Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.57 |
| ▸ | HPN | P05981 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696506 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL696505 | 1.00 | ALDH1A1 (0.68) | ALDH1A1HTTGAAHPGDPOLB | |
| Hydrochloric Acid SCHEMBL4077466 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HTTGAAHPGDPOLB | |
| Water SCHEMBL5497101 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HTTGAAHPGDPOLB | |
| Hydrochloric Acid SCHEMBL4077465 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL6302459 | 0.96 | ALDH1A1 (0.64) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL5702221 | 0.92 | ALDH1A1 (0.62) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL5702094 | 0.92 | ALDH1A1 (0.62) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL4669530 | 0.92 | ALDH1A1 (0.62) | ALDH1A1HTTGAAHPGDPOLB | |
| SCHEMBL8446614 | 0.92 | MMP2 (0.63) | ALDH1A1HTTGAAHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138266-A1 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2004-07-15 | — | — | US | claimed |
| EP-0220601-B1 | PYRANOINDOLIZINE DERIVATIVES AND PREPARATION PROCESS THEREOF | DAIICHI SEIYAKU CO., LTD. (JP) | 1991-12-11 | — | — | EP | claimed |
| EP-0220601-A1 | Pyranoindolizine derivatives and preparation process thereof | DAIICHI SEIYAKU CO., LTD. (JP) | 1987-05-06 | — | — | EP | claimed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | GONGWIN BIOPHARM CO., LTD (TW) | 2023-10-12 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-11752118-B2 | Method for treating melanoma | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| EP-0845464-A2 | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds as intermediates for camptothecin derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1998-06-03 | — | — | EP | disclosed |
| EP-0529688-B1 | Azaspiro(n,m)alkanes and diazaspiro(n,m)-alkanes | DAIICHI SEIYAKU CO (JP) | 1997-11-12 | — | — | EP | disclosed |
| US-5508428-A | Spiro compound | DAIICHI PHAMACEUTICAL CO., LTD. (JP) | 1996-04-16 | — | — | US | disclosed |
| US-5286723-A | Spiro compound | DAIICHI SEIYAKU CO., LTD. | 1994-02-15 | — | — | US | disclosed |
| EP-0357047-B1 | Spiro compounds | DAIICHI SEIYAKU CO (JP) | 1993-11-03 | — | — | EP | disclosed |
| EP-0529688-A2 | Azaspiro n,m alkanes and diazaspiro n,m -alkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| EP-0220601-B1 | PYRANOINDOLIZINE DERIVATIVES AND PREPARATION PROCESS THEREOF | DAIICHI SEIYAKU CO., LTD. (JP) | 1991-12-11 | — | — | EP | disclosed |
| US-4778891-A | Certain pyrano (3,4-f)-indolizine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1988-10-18 | — | — | US | disclosed |
| EP-0220601-A1 | Pyranoindolizine derivatives and preparation process thereof | DAIICHI SEIYAKU CO., LTD. (JP) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | LIPE, FABP4, LIPA | ALDH1A1 728/4885HTT 814/4885GAA 128/4885 |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | TP53, MCL1, TOP2B | ALDH1A1 381/4885HTT 3302/4885GAA 1313/4885 |
| US-20040138266-A1 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | PAH, HPD, CYP3A43 | ALDH1A1 263/4885HTT 3941/4885GAA 1269/4885 |
| US-11752118-B2 | Method for treating melanoma | TYR, MITF, BRAF | ALDH1A1 528/4885HTT 3063/4885GAA 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.